enGene Holdings Inc. Common Stock (ENGN) - Net Assets
Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) has net assets worth $281.55 Million USD as of January 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($337.11 Million) and total liabilities ($55.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ENGN tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $281.55 Million |
| % of Total Assets | 83.52% |
| Annual Growth Rate | 7.12% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 132.39 |
enGene Holdings Inc. Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See enGene Holdings Inc. Common Stock liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual net assets of enGene Holdings Inc. Common Stock from 2021 to 2025. For live valuation and market cap data, see ENGN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-10-31 | $167.71 Million | -38.48% |
| 2024-10-31 | $272.61 Million | +276.09% |
| 2023-10-31 | $72.49 Million | -43.11% |
| 2022-10-31 | $127.42 Million | +0.02% |
| 2021-10-31 | $127.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to enGene Holdings Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36975367800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $513.28 Million | 306.05% |
| Other Comprehensive Income | $-888.00K | -0.53% |
| Other Components | $27.35 Million | 16.31% |
| Total Equity | $167.71 Million | 100.00% |
enGene Holdings Inc. Common Stock Competitors by Market Cap
The table below lists competitors of enGene Holdings Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TTEC Holdings Inc
NASDAQ:TTEC
|
$106.56 Million |
|
Tunghsu Azure Renewable Energy Co Ltd
SHE:000040
|
$106.61 Million |
|
Severn Trent PLC
LSE:SVT
|
$106.62 Million |
|
Bionet
TWO:1784
|
$106.67 Million |
|
China Aluminum International Engineering Corporation Limited
F:4AI
|
$106.48 Million |
|
Star Holdings
NASDAQ:STHO
|
$106.47 Million |
|
Bogota Financial Corp
NASDAQ:BSBK
|
$106.38 Million |
|
Yibitas Yozgat Isci Birligi Insaat Malzemeleri Ticaret Sanayi AS
IS:YBTAS
|
$106.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in enGene Holdings Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 272,612,000 to 167,710,000, a change of -104,902,000 (-38.5%).
- Net loss of 117,302,000 reduced equity.
- Other comprehensive income increased equity by 531,000.
- Other factors increased equity by 11,869,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-117.30 Million | -69.94% |
| Other Comprehensive Income | $531.00K | +0.32% |
| Other Changes | $11.87 Million | +7.08% |
| Total Change | $- | -38.48% |
Book Value vs Market Value Analysis
This analysis compares enGene Holdings Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.22x to 0.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-10-31 | $8.06 | $1.74 | x |
| 2022-10-31 | $8.06 | $1.74 | x |
| 2023-10-31 | $3.08 | $1.74 | x |
| 2024-10-31 | $6.11 | $1.74 | x |
| 2025-10-31 | $3.28 | $1.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently enGene Holdings Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.32x
- Recent ROE (-69.94%) is below the historical average (-53.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -18.40% | 0.00% | 0.00x | 1.03x | $-36.18 Million |
| 2022 | -19.20% | 0.00% | 0.00x | 1.04x | $-37.20 Million |
| 2023 | -137.84% | 0.00% | 0.00x | 1.20x | $-107.17 Million |
| 2024 | -20.23% | 0.00% | 0.00x | 1.14x | $-82.40 Million |
| 2025 | -69.94% | 0.00% | 0.00x | 1.32x | $-134.07 Million |
Industry Comparison
This section compares enGene Holdings Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| enGene Holdings Inc. Common Stock (ENGN) | $281.55 Million | -18.40% | 0.20x | $106.51 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more